600771.SH
广誉远
SSE · Healthcare · Drug Manufacturers - General · CN
CNY 13.24
−1.49%Year over year
Reported trailing growth
- Revenue
- +11.2%
- EBITDA
- —
- EBIT
- +25.5%
- EPS
- -31.0%
- Free cash flow
- +57.8%
- Operating cash flow
- +50.0%
Forward estimates
Based on analyst estimates
- Revenue
- -48.8%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +6.6%
- EBITDA
- -2.2%
- EBIT
- -2.1%
- Net income
- -16.3%
- EPS
- -15.0%
- Free cash flow
- -7.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026